Filing Details
- Accession Number:
- 0001127602-21-010474
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-12 18:39:47
- Reporting Period:
- 2021-02-15
- Accepted Time:
- 2021-03-12 18:39:47
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 882095 | Gilead Sciences Inc | GILD | Biological Products, (No Disgnostic Substances) (2836) | 943047598 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1739307 | A Brett Pletcher | 333 Lakeside Drive Foster City CA 94404 | Evp,Corp Affairs & Gen Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-02-15 | 334 | $56.86 | 29,166 | No | 5 | A | Direct | |
| Common Stock | Acquisiton | 2021-03-10 | 2,593 | $0.00 | 31,759 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-03-10 | 1,107 | $63.91 | 30,652 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2021-03-11 | 1,486 | $63.36 | 29,166 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 5 | A | Direct | |
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Unit | Disposition | 2021-03-10 | 2,593 | $0.00 | 2,593 | $0.00 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2021-03-10 | 12,520 | $0.00 | 12,520 | $0.00 |
| Common Stock | Non-qualified Stock Option (Right to Buy) | Acquisiton | 2021-03-10 | 72,855 | $0.00 | 72,855 | $63.91 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 13,231 | No | 4 | M | Direct | ||
| 25,751 | No | 4 | A | Direct | ||
| 72,855 | 2031-03-10 | No | 4 | A | Direct |
Footnotes
- The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2020through February 15, 2021. This transaction is exempt under Rule 16b-3(c).
- In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2021.
- Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan
- The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.
- The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
- The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Billionaire Hedge Funds
